Benjamin P. Saylor

“I think what we're showing here is that the overall survival benefit, as well as the safety analysis, regardless of the number of comorbidities, was rather significant,” said study coauthor Neal D. Shore, MD.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder.

The investigators reported that overall perioperative transfusion rates were significantly lower in patients undergoing robot-assisted radical cystectomy.

“Using a national cohort of older adults with dementia, we…found that donepezil was associated with a 13% increased risk of OAB compared to rivastigmine,” says study author Rajender R. Aparasu, PhD

“We’ll be able to take a drop of blood in a community setting such as a barbershop and be able to deliver results in 10 to 15 minutes right there,” says investigator Saurabh Mehta, ScD.

The investigators found that the overall upstaging rate from re-TURBT to RC was 34.9%, with 31.0% upstaged in the NAC group and 37.0% in the no-NAC group (P = .584).

“This post hoc analysis demonstrates that enzalutamide plus ADT provides clear clinical benefits in improving survival, delaying progression, and other secondary end points in patients with oligometastatic disease,” says Andrew J. Armstrong, MD, MSc.

“These findings are exciting because we’re challenging the dogma in radiation oncology that RCC is biologically radioresistant," ,” said lead author Chad Tang, MD.

“After 2 years, patients reported no increase in urinary or bowel side effects with the shorter course and its effectiveness was comparable,” said Mark Buyyounouski, MD.

According to the investigators, their findings were consistent with initial real-world experience with oral testosterone undecanoate indicating that dose titration is not required in most patients.

Over the observation period, 15 patients (8.2%) in the treatment group died compared with 61 patients (34.3%) in the control group.

There were no clinically significant changes in liver function tests throughout the 2 trials.

As indicated by regression analysis, there was a significant association between the degree of penile curvature and status of uncontrolled diabetes mellitus.

“Qmax at 1, 3, 6, 9, and 12 months and voiding volume at 3 months were significantly lower in the impaired group than in the preserved group. This suggests that preoperative lower bladder contractility was associated with prolonged deterioration of voiding function,” says Junya Hata, PhD.

“We found that in patients presenting with LUTS, there is an association between urinary incontinence and [worse] sexual function,” said study author Giuseppe Fallara, MD.

Unadjusted real-world overall survival was longer in patients receiving first-line cisplatin compared with patients receiving other first-line treatments.

The hard-to-treat subgroups consisted of age 65 years or older, presence of liver metastasis, primary upper tract disease, and nonresponse to prior PD-1/L1 inhibitor treatment.

Investigators also found high concordance between the Guardant Health (360 or Omni) assays and FoundationOne CDx for the detection of BRCA and HRR mutations.

“At 365 days, the rate of return procedures was lowest for the UroLift. The rate of return procedures was higher after Rezum versus UroLift,” says Steven A. Kaplan, MD.

“Darolutamide was associated with a reduction in locally invasive procedures and delayed time to deterioration in patient health-related quality of life with respect to urinary and bowel symptoms,” says Neal D. Shore, MD, FACS.

“In a real-world clinical setting, providers representing a broad range of practice styles, settings, education, and experience readily adopted IsoPSA to help risk stratify and generated about a 50% reduction in the number of prostate biopsies recommended,” said Eric A. Klein, MD.

“Level 1 data on shock wave therapy for ED is still pending. It should not be marketed as having such,” says James Weinberger, MD, MBA.

The novel oncolytic immunotherapy CG0070 is also currently being explored as a in a phase 3 monotherapy trial.

In a news release, Checkmate -274 primary investigator Matthew Galsky, MD, hailed the approval as a “major milestone for patients who have undergone major surgery to remove the bladder or parts of the urinary tract and are in need of additional treatment approaches that can help reduce the risk of their UC returning."

Investigators report that high urinary cotinine levels are associated with a greater risk of recurrence in smokers.

Integrating immunotherapy into bladder-sparing approaches may enhance the efficacy and uptake of these strategies in bladder cancer.

Patients with African ancestry were also less likely to be treated on clinical trials versus patients with European ancestry, the investigators reported.

A 1-year bladder-intact disease-free survival rate of 89% was observed across the entire phase 2 study cohort.

The treatment was also well tolerated, results from an ongoing phase 1/2a dose escalation study indicate.